Experts Matter. Find Yours.
Connect for media, speaking, professional opportunities & more.
Covering 4/20? Our experts can help you see through the smoke | Media Advisory
As 4/20 approaches, the spotlight once again turns to the evolving landscape of marijuana legalization and its broader societal impacts. This annual observance not only marks a cultural moment for cannabis enthusiasts but also prompts discussions about the legal, economic, and public health implications of marijuana use in the United States. Here are key story angles for journalists to explore: Legalization efforts and state-by-state updates: Tracking the progress of marijuana legalization initiatives across the country and analyzing the legal frameworks governing recreational and medicinal cannabis use. Economic opportunities and challenges: Investigating the economic impact of the cannabis industry, including job creation, tax revenue generation, and business opportunities, as well as regulatory hurdles and market fluctuations. Social justice and equity in cannabis legalization: Examining efforts to address historical inequities in drug enforcement and incarceration through policies such as expungement, social equity programs, and community reinvestment. Public health and safety considerations: Assessing the health effects of marijuana use, the regulation of cannabis products, and efforts to mitigate potential risks such as underage consumption and impaired driving. Cannabis culture and mainstream acceptance: Exploring the evolving perceptions of marijuana in society, including trends in consumption habits, cannabis tourism, and its portrayal in media and popular culture. International perspectives on marijuana policy: Comparing approaches to marijuana legalization and regulation in other countries and evaluating lessons learned for U.S. policymakers and stakeholders. Connect with an Expert about Marijuana in America: For journalists with questions or looking to cover the streaming wars? here is a select list of experts. To search our full list of experts visit www.expertfile.com Robert Mikos Professor of Law · Vanderbilt University Michael Ostrowsky Professor of Sociology · Southern Utah University Jennifer Whitehill Associate Professor of Health Policy and Management · University of Massachusetts Amherst Daniele Piomelli Distinguished Professor · UC Irvine Almut Winterstein Distinguished Professor · University of Florida Photo Credit: Dylan Mullins
Professor Roslyn Bill discusses her research into brain cell membranes with Dr Matt Derry Serious brain injuries and dementia are affected by the flow of water through a protein called aquaporin-4 in brain cell membranes Aquaporins are responsible for clearing the build-up of waste products in brain cells in a process Professor Bill likens to a ‘dishwasher for your brain’. Professor Roslyn Bill, co-founder of Aston Institute for Membrane Excellence (AIME), joins Dr Matt Derry to discuss her research into brain cell membranes in the latest Aston Originals podcast. Water moves in and out of brain cells through tiny protein channels in the cell membrane called aquaporins. One in particular, aquaporin-4, is the focus of Professor Bill’s research. In 2020, she was lead author on a paper published in prestigious journal Cell on how the channels open and close and how this can be controlled. Uncontrolled water entry into brain cells can occur after head trauma, causing swelling which leads to severe brain injuries of the type suffered by racing driver Michael Schumacher after a skiing accident. Finding drugs to control this water movement could lead to treatments to prevent brain swelling in the first place. This research into brain swelling and the contribution of aquaporins led Professor Bill to research into Alzheimer’s, a common form of dementia, which is also related to the action of aquaporins. Alzheimer’s is caused by a build-up of waste products in brain cells. In a process Professor Bill likened to a ‘dishwasher for your brain’, aquaporins are responsible for clearing this waste as we sleep. Professor Bill was selected for an Advanced Grant by the European Research Council (ERC) in 2023, which is being funded by UK Research and Innovation (UKRI). The funded project will further investigate the process, and whether it might be possible to develop a drug to boost the ‘brain dishwasher’, which could be taken to slow or even prevent cognitive decline due to ageing. Bringing together this biological research with the polymer research of AIME, chemists like Dr Derry will help in the drug development and could also lead to totally different applications. Professor Bill said in the podcast to Dr Derry: “We can take the knowledge that we have of how these proteins work in cells and try and apply them to interesting applications in biotechnology. And this is where the sort of work that you (Dr Derry) do comes in, where you can develop plastic membranes, polymer membranes, and then take learning from the biology and try and make really, really good ways of purifying water, for example.” For more information about AIME, visit the webpage. The website also includes links to the previous AIME podcast and details about open positions.
Aston University pharmaceutical spin-out company shortlisted in life sciences industry awards
MESOX is a spin-out from the pharmaceutics group at Aston Pharmacy School The company partners with pharmaceutical and biotechnology companies to bring challenging therapeutics to market It has been shortlisted in the Medilink Midlands Awards 2024. A spin-out company from Aston University’s pharmaceutics research group has been shortlisted for a life sciences industry award. The Medilink Midlands Awards aim to showcase the very best collaborations between industry, academia and the NHS across the Midlands. The company, MESOX, founded by Dr Ali Al-Khattawi, a lecturer in pharmaceutics at Aston Pharmacy School, is competing in the Start-Up category for newly established companies that show a promising future. With in-depth expertise in particle engineering for drug delivery and pharmaceutical spray drying, MESOX uses IP-protected carriers to improve the bioavailability and efficacy of pharmaceuticals, partnering with pharmaceutical and biotechnology companies to bring challenging therapeutics to market. Medilink Midlands provides specialist business support to boost the region’s economic output from the life sciences industry. Working alongside the Midlands Engine and other strategic alliances, it helps stimulate additional and value-added growth of the Midlands as a prosperous community for life sciences. The awards winners will be announced at a ceremony taking place on Thursday 9 May at the Athena in Leicester. To celebrate Medilink Midlands’ 20th year anniversary of delivering business support, one finalist will be announced as the 2024 ‘Winner of all Winners’ and presented with a £5,000 prize for innovation development. Dr Ali Al-Khattawi, founder and CEO of MESOX, said: “We are excited to be nominated as a finalist for this award, which is a testament to the innovative research at Aston University that has led to MESOX and a great way to recognise the efforts of our team. “MESOX is expediting the development of life-saving therapeutics through cutting-edge carrier technologies. Our vision is to be a leading research-based pharmaceutical company in the Midlands one day and we hope this opportunity brings us a step closer to this goal.” Luke Southan, technology transfer manager at Aston University, said: “Aston University’s School of Pharmacy has always been a hotbed of innovation and entrepreneurship. This is most often seen through our many students who end up running their own independent pharmacy stores, but it is also the school that has created the most Aston spinouts. “MESOX is the latest example of this, and it is a company that is on track to be generating significant revenue and region impact over the next five years. This award nomination evidences the potential the company has to offer.”
Aston University and medicine manufacturer Catalent formed a Knowledge Transfer Partnership to identify more effective formulation additives The new selection matrix makes choosing the right additive quicker and the medicine development process shorter The project has been rated as ‘outstanding’ by Innovate UK A partnership between Aston University and contract medicine manufacturer Catalent has led to a faster process to identify the best ingredients for optimal medicine formulations, and has been rated as outstanding by Innovate UK. Catalent is a global leader in enabling pharma, biotechnology and consumer health partners to optimise product development, launch and full life-cycle supply for patients around the world. Its proprietary Zydis orally dissolving tablet (ODT) technology enables the absorption of drugs or active pharmaceutical ingredients (APIs) through the mouth tissues, which is much faster than absorption through the gut. However, many APIs have poor pre-gastric absorption and need to be combined with suitable excipients, or additives, to bind the active ingredients and speed up the process of dissolving and absorbing via the pre-gastric route. Identifying suitable excipients for the formulation is difficult, and so the Knowledge Transfer Partnership (KTP) between Aston University and Catalent was set up to develop a faster, more efficient approach. A KTP is a three-way collaboration between a business, an academic partner and a highly qualified researcher, known as a KTP associate. The UK-wide programme helps businesses to improve their competitiveness and productivity through the better use of knowledge, technology and skills. Aston University is a sector leading KTP provider, with 80% of its completed projects being graded as very good or outstanding by Innovate UK, the national body. The project was led by Aston University’s Afzal Mohammed, professor of pharmaceutics in the School of Pharmacy and associate dean (impact and knowledge exchange) for the College of Health and Life Sciences, who has expertise in the design and optimisation of orally dissolving tablet formulation. He was supported by other colleagues from Aston Pharmacy School including Dr Daniel Kirby, whose main area of research is the formulation of age-appropriate medicines for the extremes of life, Dr Affiong Iyire, who has research expertise in mucosal drug delivery, and Dr Raj Badhan, who is a pharmacokinetics expert with research interests in analytical approaches to predict oral drug absorption. Dr Ruba Bnyan, who has a master’s degree and a PhD in pharmaceutical drug formulation, as well as experience in cell-based models, was the KTP associate for the project. The KTP partners developed a selection matrix, whereby, based on the API properties, Catalent formulation scientists can quickly identify excipients that will improve the absorption of the drug through the mouth. Adopting this novel tool allows for quicker and more efficient drug development and has the potential to increase the number of Zydis ODT candidates in the pipeline for future development. Desmond Wong, product development supervisor at Catalent, said: “This project has exceeded our initial expectations and has the potential to accelerate product development for our clients. Our strong relationship with the Aston University team on this KTP project highlights the transformative potential of collaborative research and its impact on pharmaceutical innovation.” Professor Mohammed said: “This has been a very successful project, which has been rated as ‘outstanding’ by Innovate UK. We plan to put it forward for a KTP award and are looking forward to continuing working with Catalent on our next KTP project.” For more information on the KTP visit the webpage.
#Expert Q&A: NJIT’s David Bader on AI, Data Science, Quantum Computing
Artificial intelligence, data science and the emerging field of quantum computing are among the hottest research topics in computing today. David Bader, a distinguished professor at New Jersey Institute of Technology’s Ying Wu College of Computing and the director of the university’s Institute for Data Science, offers his take on each. The Computer History Museum has recognized you for developing a Linux supercomputer using commodity hardware. Was that a life-shaping lesson? It was a venture into the unknown, leveraging the emerging potential of Linux and commodity hardware to build something that was both accessible and powerful. This experience taught me the importance of embracing risk and the value of resilience. There were technical hurdles, skepticism from peers and the daunting task of venturing beyond established norms. Also, the Linux supercomputer project was not just about the technology. It was about building a community around an idea. How do user-friendly AI systems like ChatGPT impact your work? It enriches the palette of methodologies and technologies at our disposal, enabling us to tackle more ambitious projects with greater efficiency and creativity. By integrating these AI systems into our research and educational programs, we're not just enhancing our ability to process and analyze data. We're also empowering students and researchers with the means to innovate and explore new horizons in data science without being hindered by the technical complexities that once acted as barriers. Some information workers fear that AI will make their careers obsolete. But tech progress can’t be stopped, so how should people adapt? By embracing these technologies, learning to work alongside them and leveraging their capabilities to enhance our own skill sets and productivity. Also, it's important to focus on the uniquely human skills that AI cannot replicate, such as creativity, emotional intelligence and critical thinking. By honing these abilities, workers can ensure they remain irreplaceable components of the workforce, capable of tasks that require a human touch — from complex decision-making to empathetic interactions with customers or clients. What should non-programmers learn about AI? It’s important to be aware of how AI decisions are made, the potential biases in AI systems and the ethical considerations of AI use. Additionally, developing data literacy is crucial, as it enables individuals to evaluate AI outputs and understand the importance of data quality and biases. A basic grasp of AI and machine learning concepts — even without programming skills — can demystify AI technologies and reveal their potential applications. Staying informed about AI advancements across various sectors can also inspire innovative ideas and foster interdisciplinary collaborations. There’s a sci-fi plot where computers get so smart that people lose control. The new class of user-friendly AI is making people excited but also nervous. Should we be afraid? While it’s natural to harbor concerns about the rapid progression of AI, allowing fear to dominate the discourse would be a disservice to the potential benefits these technologies can offer. Instead, this moment calls for proactive engagement with AI and an investment in understanding its inner workings, limitations and the ethical dilemmas it presents. By advocating for responsible AI development, emphasizing education and promoting transparency, we can foster an environment where AI serves as a tool for societal advancement. This approach ensures that we remain at the helm of AI's trajectory, steering it toward outcomes that uplift humanity rather than scenarios that fuel dystopian fears. What other emerging technologies excite you in their potential to transform computing? Quantum computing. This technology, with its potential to solve complex problems exponentially faster than classical computers, could revolutionize fields ranging from cryptography to drug discovery, climate modeling and beyond. Quantum computing's promise to tackle challenges currently beyond our reach, due to its fundamentally different approach to processing information, represents a leap forward in our computational capabilities. Its convergence with AI could lead to unprecedented advancements, making this era an incredibly thrilling time to be at the forefront of computing and data science. Looking to know more? We can help. David Bader is available to discuss AI, quantum computing and data science with media. Simply click on his icon to arrange an interview.
Oprah Hosts Primetime Special About Weight Loss Drugs on ABC | Media Advisory
Oprah Winfrey, a revered media mogul and advocate for health and wellness, is set to host a groundbreaking primetime special on ABC, focusing on the burgeoning field of weight loss drugs. The new special follows Winfrey’s exit from the board of weightwatchers, where she served for nearly a decade after acquiring a 10% stake in the company. This special promises to shed light on the science behind popular weight loss medications Ozempic, Mounjaro and Wegogy. As obesity rates continue to climb globally, the discussion around weight loss solutions becomes increasingly pertinent, touching on public health, self-image, and the pharmaceutical industry's role in shaping health standards. Key topics of interest include: Science and Effectiveness of Weight Loss Drugs: Exploring how these medications work and their success rates. Personal Stories of Transformation: Individuals' journeys with weight loss drugs, including challenges and triumphs. Ethical and Societal Implications: The debate over body image, health standards, and drug dependency. Regulatory Perspective and Safety: How these drugs are approved and monitored for public use. Impact on the Healthcare System: The potential effects on healthcare costs and accessibility. Cautions and Concerns: Are there serious side-effects and what are the risks related to taking these drugs? Future of Obesity Treatment: Innovations and next steps in treating obesity with pharmaceuticals. For journalists seeking research or insights for their coverage on this topic, here is a select list of experts. Rebecca Puhl, Ph.D. Professor of Human Development and Family Studies · University of Connecticut Professor Paul Gately Carnegie Professor of Exercise and Obesity and Co-Director of the Applied Centre for Obesity Research · Leeds Beckett University Rebecca Pearl Assistant Professor · University of Florida Jan D. Hirsch Founding Dean, School of Pharmacy and Pharmaceutical Sciences · UC Irvine Amy Gorin, Ph.D. Professor, Department of Psychological Sciences · University of Connecticut James Lenhard, Jr., M.D., FACE, FACEP Medical Director · ChristianaCare To search our full list of experts visit www.expertfile.com. Photo by Total Shape
Since 2022, the U.S. Food and Drug Administration has been actively urging consumers to avoid purchasing or consuming tianeptine -- a synthetic drug commonly called "gas station heroin" that can mimic the actions of opioids like fentanyl. Now, the FDA is upping the urgency of it's warnings as vendors continue to market the drug as a so-called "dietary supplement." UConn's C. Michael White, a Distinguished Professor of Pharmacy Practice, spoke with The Conversation about the problem with tianeptine in a must-read Q-and-A: What is tianeptine and why is it risky? Tianeptine stimulates the same receptors as well-known opioids such as fentanyl, heroin and morphine. When these drugs make their way from the blood to the brain, they bind to the “mu” type opioid receptor that triggers the sought-after pain relief and euphoria of those drugs as well as the dangerous effects like slowed or stopped breathing. High doses of tianeptine can bring euphoric effects similar to heroin and can also bring about the dissociative effect – the perception of your mind being disconnected from your surroundings and body – that is reminiscent of ketamine, an anesthetic that has a role in treating post-traumatic stress disorder and depression but has also commonly been abused as a street drug. Products containing tianeptine are often called “legal high drugs” – sometimes dubbed “gas station drugs” – a term used for all non-FDA-approved synthetic drugs that are sold casually in gas stations, online and elsewhere. What are the major adverse effects that people can experience? Data from clinical trials, case reports and poison control centers shows that tianeptine commonly induces agitation. This is typically accompanied by a fast heart rate and high blood pressure, confusion, nightmares, drowsiness, dry mouth and nausea, among other conditions. The most serious adverse events are slowed or stopped breathing, coma, heart arrhythmia and death. When long-term users try to stop tianeptine use, they often experience withdrawal symptoms reminiscent of opioid withdrawal. Consumers need to be aware that products containing tianeptine may not adhere to good manufacturing practices. This means they could contain lead or have other heavy metal contamination or be contaminated by microorganisms such as salmonella or mold. They could also contain other drug ingredients that are not disclosed. Knowingly or unknowingly combining active ingredients can increase the risk of adverse events. Additionally, the amount of the active ingredient contained in the product can vary widely, even with the same manufacturer. So past use does not guarantee that using the same amount will provide the same effect. How are these drugs sold in the US if they are not FDA-approved? If a drug product is not FDA-approved for prescription or over-the-counter-use, it is the Drug Enforcement Agency that is responsible for controlling market access. Before the DEA can ban an active ingredient in a drug product, it must be designated Schedule I, meaning the drug has no legitimate medical purpose and has high abuse potential. Manufacturers do not have to alert the DEA before selling their products to U.S. citizens. This means the DEA must detect an issue, identify the products causing the issue, identify the active ingredients in the product in question and do a full scientific review before designating it as Schedule I. Tianeptine came to market masquerading as a dietary supplement in gas stations and smoke shops, even though it is a synthetic compound. Tianeptine is also sold online allegedly for research purposes and not for human consumption. Tianeptine is undergoing clinical trials for the treatment of pain and depression, but sellers do nothing to make this type of labeling clear to consumers or to restrict purchases to researchers. What can people do to protect themselves and their families? Non-FDA-approved products containing synthetic drugs are very risky to use and should be avoided. FDA-approved drugs are available by a prescription from a health professional or over the counter with active ingredients on an approved list. If someone in a gas station, smoke shop or over the internet touts the benefits of a non-FDA-approved drug product – for pain or anxiety relief, to increase energy or for a buzz – be aware. It could be dangerous the first time you use it, but using it successfully once also doesn’t mean the experience will be the same the next time, and continued use can cause addiction. If a product is being sold “not for human consumption” or “for research purposes only,” you are at a high risk if you take it. Before you take any dietary supplement, make sure you check the active ingredient to be sure that it is, in fact, a natural product and not a synthetic chemical. If someone you know has bags with unmarked powder, a product labeled for research use or not for human consumption, or tablets or capsules not in standard drug bottles, that is a sign of a potentially dangerous situation. Standard drug tests sold over the counter are not designed to pick up tianeptine. One of the main reasons that people use these alternative substances of abuse over regular opioids, cannabis or amphetamines is that they are much harder to detect through work- or at-home drug screens by parents, schools, employers, probation officers and so on. If the DEA is not responding to emerging threats quickly enough, individual states can also act to ban sales of dangerous active ingredients in products. As of January 2024, at least 12 states have banned the sale of tianeptine, according to the FDA, although people in those states can still illegally procure it from the internet. So contacting your state legislators could be a place to start exercising your power to help prevent the harms from these products. This is an important piece, and if you are looking to know about tianeptine and the threat it poses to consumers in America, then let us help. Dr. C. Michael White is an expert in the areas of comparative effectiveness and preventing adverse events from drugs, devices, dietary supplements, and illicit substances. Dr. White is available to speak with media -- click on his icon now to arrange an interview today.
Image shows how tiny water channels control how water enters and exits cells through their membranes The Aston Institute for Membrane Excellence (AIME) will be set up with a £10m grant from Research England AIME will be led by Professor Roslyn Bill from Biosciences and Professor Paul Topham from Chemical Engineering and Applied Chemistry The globally unique institute will use biomimetic polymer membranes for applications such as water purification and drug development Aston University will establish the Aston Institute for Membrane Excellence (AIME), a globally unique, cross-disciplinary institute to develop novel biomimetic membranes, after receiving a major grant of £10m from Research England. AIME will be led by Professor Roslyn Bill, from the School of Biosciences, with co-lead Professor Paul Topham from the department of Chemical Engineering and Applied Chemistry (CEAC). Membranes, both biological and synthetic, are hugely important in many sectors. For example, the world’s top ten selling human medicines all target proteins in biological membranes, while synthetic polymer membranes are used in the US$100bn/year water purification industry. The team behind AIME believes that the full potential of membranes will only be realised by an interdisciplinary group spanning biology, physics and chemistry that can investigate membranes holistically. Professor Bill, a European Research Council (ERC) Advanced grantee leads Aston Membrane Proteins and Lipids (AMPL) research centre of excellence that studies the structure and function of membrane proteins and associated lipids. Professor Topham leads Aston Polymer Research Group (APRG), which investigates the nanoscale behaviour of block copolymers (a type of polymer with a structure made of more than one type of polymer molecule) and polymer technologies for membranes. AMPL and APRG have already begun collaborative research and AIME will bring together the complementary expertise of both research clusters into one institute. AIME will initially comprise the eight researchers from AMPL and APRG. Alongside the co-leads Professor Bill and Professor Topham, will be Dr Alan Goddard, Professor Andrew Devitt, Professor Corinne Spickett, Dr Alice Rothnie, Dr Matt Derry and Dr Alfred Fernandez. It plans to recruit three further academics, six tenure-track research fellows, three postdoctoral research assistants (PDRAs), six PhD students, a research technician and a business development manager. Importantly, AIME will work with many existing Aston University colleagues to build a comprehensive research community focused on all aspects of membrane science. The new AIME team will focus on the development of bioinspired, highly selective polymer structures for applications in water purification and waste remediation, nanoparticles loaded with therapeutic molecules to treat disorders ranging from chronic wounds to neurological injuries, and the purification of individual membrane proteins with polymers to study them as drug targets. The vision is for AIME to become a ‘one-stop shop’ for interdisciplinary, translational membrane research through its facilities access and expertise, ideally located in the heart of the country. Professor Bill said: “The creation of AIME is ground-breaking. Together with Aston’s investment, E3 funding will deliver a step-change in scale and the rate at which we can grow capacity. We will address intractable scientific challenges in health, disease, and biotechnology, combining our world-class expertise in polymer chemistry and membrane biology to study membranes holistically. The excellence of our science, alongside recent growth in collaborative successes means we have a unique opportunity to deliver AIME’s ambitious and inclusive vision.” Professor Topham said: “We are really excited by this fantastic opportunity to work more closely with our expert colleagues in Biosciences to create advanced technology to address real world problems. From our side, we are interested in molecular engineering, where we control the molecular structure of new materials to manipulate their properties to do the things that we want! Moreover, we are passionate about a fully sustainable future for our planet, and this investment will enable us to develop technological solutions in a sustainable or ‘green’ way.” Professor Aleks Subic, Vice-Chancellor and Chief Executive of Aston University, says: “Our new Aston Institute for Membrane Excellence (AIME) will be a regional, national, and international research leader in membrane science, driving game-changing research and innovation that will produce a pipeline of high-quality research outcomes leading to socioeconomic impact, develop future global research leaders, create advanced tech spinout companies and high value-added jobs for Birmingham and the West Midlands region. Its establishment aligns perfectly with our 2030 strategy that positions Aston University as a leading university of science, technology and enterprise.” Steven Heales, Policy Manager (Innovation) at the West Midlands Combined Authority, said: “WMCA is delighted to see Research England back the Aston Institute for Membrane Excellence. This will enable Aston University’s excellent academics and research community to work closely with businesses to make advances in membrane technology and applications. “In 2023 the West Midlands Combined Authority agreed a Deeper Devolution Trailblazer Deal with Government, which included a new strategic innovation partnership with Government. Projects like AIME are exactly the kind of impact we expect this new partnership to generate, so watch this space.” Lisa Smith, chief executive of Midlands Mindforge, the patient capital investment company formed by eight Midlands research-intensive universities including Aston University, said: “This grant is an important vote of confidence in the Midlands scientific R&D ecosystem. AIME will play an important role in the future research of pioneering breakthroughs in membrane science and enable the world-leading research team at Aston University to develop solutions to real world problems. We look forward to closely working with the Institute and nurturing best-in-field research being undertaken at Aston out of the lab and into the wider society so it can make a positive impact”. Rob Valentine, regional director of Bruntwood SciTech, the UK’s leading developer of city-wide innovation ecosystems and specialist environments and a strategic partner in Birmingham Innovation Quarter, said: "As a proud supporter of the Aston Institute for Membrane Excellence (AIME), I am thrilled at the launch of this groundbreaking initiative. AIME exemplifies Aston University's commitment to advancing cutting-edge interdisciplinary research and further raises the profile of the region’s exemplary research capabilities and sector specialisms. AIME's vision of becoming a 'one-stop shop' for translational membrane research, strategically located at the heart of the country, aligns perfectly with our strategy at Bruntwood SciTech. We are committed to working with partners, including Aston University, to develop a globally significant innovation district at the heart of the UK where the brightest minds and most inspiring spaces will foster tomorrow’s innovation.” Membrane research at Aston University has also recently received two other grants. In November 2023, Professor Bill received £196,648 from the Biotechnology and Biological Sciences Research Council’s Pioneer Awards Scheme to understand how tiny membrane water channels in brain cells keep brains healthy. In December 2023, a team led by AIME team-member Dr Derry received £165,999 from the Engineering and Physical Sciences Research Council to develop biomimetic membranes for water purification. For more information about AIME, visit the webpage.
Below is a statement from Eric Kmiec, Ph.D., founder and executive director, ChristinaCare Gene Editing Institute, regarding the expected approval by the Food and Drug Administration of exa-cel (Casgevy), the CRISPR-driven treatment for sickle cell disease and betta thalassemia. If you wish to interview Dr. Kmiec, please contact Mak Sisson, Makenzie.sisson@christinacare.org,302-623-5306 or Anna Chen, achen@burness.com, 215-262-7670. “As scientists, the fact that we have arrived at a potential curative treatment for sickle cell disease in a relatively brief period is a testament to the power of resolute researchers in this field who have never stopped. And the FDA’s expected approval comes with many firsts. For the first time we have what appears to be a safe and curative treatment for one of the most painful diseases that cuts life short. And it is remarkable that finally we are focusing on the Black population first, who are most affected by this disease. This priority is long, long overdue. The challenge, however, is the very people we want to help may not be able to get access to or afford the million-dollar treatment and the length of time it will take to be treated — weeks and weeks in the hospital. The numbers of people who can be treated are limited. We must work with the health care industry and pharmaceutical companies who will market produce and deliver the treatments to make sure that all people can get access. What can they do to make treatments more affordable and more available? What can they do to support continued research to assess the long-term effects this treatment may have? And how can we make this easier to deliver? As important as it is to have developed this new treatment, right now we must do our best to communicate well to the public what new findings like this mean. Take the time to explain it all. It cannot be oversold. We must make the communication about this first CRISPR-driven treatment as important as the science itself.” Eric B. Kmiec, Ph.D., is the founder and executive director of the Gene Editing Institute at ChristianaCare. He is also co-founder and chief scientific officer of CorriXR Therapeutics. Widely recognized for his pioneering work in the fields of molecular medicine and gene editing, Dr. Kmiec has developed CRISPR based genetic therapies for Sickle Cell Disease and Non-Small Cell Lung Cancer. He is Editor-in-Chief of the journal, Gene and Genome Editing.
Peer Support Program Helps Patients With Substance Use Disorders
Recognizing that stigma may keep people from accessing treatment and recovery resources, ChristianaCare Union Hospital is partnering with the Cecil County Health Department and Voices of Hope to make peer recovery specialists available at the bedside for patients who have experienced a drug overdose or live with substance use disorder. Ten peer recovery specialists are available at Union Hospital seven days a week from 8:30 a.m. to 1 a.m. to talk with patients about behavioral health care navigation, access to treatment and referrals to harm-reduction and recovery-support resources. Patients can be connected with a certified peer recovery specialist if they are brought to the Emergency Department because of a drug overdose, or if they screen positive for substance use while they are a patient in the hospital. ChristianaCare Union Hospital is partnering with the Cecil County Health Department and the Maryland nonprofit Voices of Hope to make peer recovery specialists, pictured in blue t-shirts, available at the bedside for patients who have experienced a drug overdose or live with substance use disorder. Patients are not required to speak with a peer recovery specialist, but the specialists’ unique combination of lived experience and training to help people experiencing behavioral health issues offers an opportunity for people with substance use disorder to get help without fear of judgment or stigma. “Substance use disorder continues to be a serious health problem that affects people of all ages and walks of life,” said Lanre Akinkunmi, M.D., interim chief medical officer and medical director for population health at ChristianaCare Cecil County Campus. “The good news is that it is treatable, and when people are in the hospital or the emergency department, they are often most receptive to discussions about treatment. Through this expanded use of peer recovery specialists at Union Hospital, we are making a positive impact on the health of our patients and our community.” A voice of experience Peer recovery specialists who work on the weekdays are employed by the Cecil County Health Department, supported by a grant from the National Association of County and City Health Officials. Voices of Hope, a nonprofit focused on recovery support for people in Harford and Cecil counties in Maryland, employs the peer specialists working evenings and weekends. “This program is a great example of using resources wisely and effectively. We already know the tremendous work being done by Voices of Hope and Cecil County Health Department to help our neighbors who have been impacted by substance use disorder,” said Lisa Fields, manager of Community Engagement at the Cecil County Campus. “By partnering on this important program, we are building trust with our patients and helping them to get on the road to recovery.” Since the expanded program launched in September, there have been about 40 referrals for patients to speak with peer support specialists, and more than half of them have agreed to some kind of treatment, Fields said. Unique connection “Helping people get through what I went through really warms my heart,” said Hannah Dean, a peer recovery specialist with the Cecil County Health Department who works at Union Hospital. “I love what I do.” Cecil County’s death rate from drug overdoses is nearly twice as high as the rest of Maryland and more than three times the U.S. rate. The drug overdose death rate in Cecil County more than doubled between 2016 and 2020, according to the 2022 Cecil County Community Health Needs Assessment. Because peer support specialists have lived experience with substance use disorder and recovery, along with specialized training to support people struggling with mental health or substance use issues, they can connect with patients on a personal level and offer empathetic guidance, said Lauren Levy, health officer for the Cecil County Health Department. “Allowing peer recovery specialists to engage bedside with patients who may be struggling with substance use disorders will not only enhance access to behavioral health treatment but will also help reduce stigma surrounding substance use disorders and foster a more compassionate and supportive community,” Levy said. “We are honored to be a part of this innovative private-public collaboration and to work alongside ChristianaCare Union Hospital and Voices of Hope, Inc. This project helps to break down barriers to treatment and provide immediate support to those in need.” A history of support ChristianaCare has long been a pioneer in the use of peer recovery specialists, going back to the launch of Project Engage at ChristianaCare’s Wilmington Hospital in 2008. Union Hospital first partnered with the Cecil County Health Department 10 years ago to provide a peer recovery specialist in the Emergency Department. That program, the first of its kind in Maryland, was recognized with a best practice award from the Maryland Association of Counties in 2014. However, it operated only on weekdays during daytime business hours, and its ability to connect with hospital patients slowed during the COVID-19 pandemic. This reinvigorated peer recovery program is strengthened by the high level of collaboration among these Cecil County organizations, said Erin Wright, chief operations officer for Voices of Hope. “As community-based organizations, we are in a position to make a difference, and our perspective in the care for people with substance use disorder is really valuable,” said Wright, who has been in recovery for eight years. “As someone who has been through it, we are able to have that empathy. Even if the person does not want to go to treatment, you sit with them and maybe plant a seed.” Catharine Murray hopes her role as a certified peer recovery specialist can help someone struggling with addiction see recovery as a viable option for themselves. “This wasn’t available to me when I was trying to get better. I want to make it more accessible to others,” she said.